Hereditary angioedema (HAE) with C1 inhibitor deficiency is a genetic disorder that clinically manifests with attacks of angioedema in the subcutaneous and submucosal tissues, mainly in the extremities, abdomen, and upper airway. During attacks, vascular permeability is increased due to increased bradykinin (BK). This means that special therapies are needed for attacks that do not respond to traditional antiallergic therapies involving antihistamines, corticosteroids, and epinephrine. The recurring attacks may disable patients and lead to frequent visits to emergency rooms where misdiagnoses are common. HAE attacks may be fatal when upper-airway edema occurs, if proper treatment with a C1 inhibitor concentrate or BK receptor antagonist is not administered or an emergency tracheostomy is not performed. We propose a mnemonic method for the warning signs of HAE for the use as a diagnostic tool, i.e., the so-called “ABC” of the warning signs of HAE. The letters represent the following: A = Angioedema, B = Bradykinin, C = C1 inhibitor, D = Distress factors, E = Epinephrine nonresponsive, F = Family history, and G = Glottis/Gastrointestinal edema. To avoid fatalities, medical staff and patients, including family members, must be aware of HAE. An alphabetical mnemonic method has been developed and we hope it may benefit patients.

Keywords:
Warning signs, Hereditary angioedema, Diagnosis, Emergency care
1.
Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, Caballero T, Farkas H, Grumach A, Kaplan AP, Riedl MA, Triggiani M, Zanichelli A, Zuraw B: Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 2014;69:602-616.
2.
Bork K, Barnstedt SE, Koch P, Traupe H: Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000;356:213-217.
3.
Cagini N, Veronez CL, Constantino-Silva RN, Buzolin M, Martin RP, Grumach AS, Velloso LA, Mansour E, Pesquero JB: New mutations in SERPING1 gene of Brazilian patients with hereditary angioedema. Biol Chem 2016;397:337-344.
4.
Dewald G, Bork K: Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 2006;343:1286-1289.
5.
Cichon S, Martin L, Hennies HC, Müller F, Van Driessche K, Karpushova A, Stevens W, Colombo R, Renné T, Drouet C, Bork K, Nöthen MM: Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006;79:1098-1104.
6.
Bossi F, Fischetti F, Regoli D, Durigutto P, Frossi B, Gobeil F Jr, Ghebrehiwet B, Peerschke EI, Cicardi M, Tedesco F: Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. J Allergy Clin Immunol 2009;124:1303-1310.
7.
Grumach AS, Valle SOR, Toledo E, de Moraes Vasconcelos D, Villela MMS, Mansour E, Pinto JA, Campos RA, França AT; Group interested in HAE (GINHA): Hereditary angioedema: first report of the Brazilian registry and challenges. J Eur Acad Dermatol Venereol 2013;27:e338-e344.
8.
Bork K, Hardt J, Witzke G: Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 2012;130:692-697.
9.
Cugno M, Castelli R, Cicardi M: Angioedema due to acquired C1-inhibitor deficiency: a bridging condition between autoimmunity and lymphoproliferation. Autoimmun Rev 2008;8:156-159.
10.
Javaud N, Achamlal J, Reuter PG, Lapostolle F, Lekouara A, Youssef M, Hamza L, Karami A, Adnet F, Fain O: Angioedema related to angiotensin-converting enzyme inhibitors: attack severity, treatment, and hospital admission in a prospective multicenter study. Medicine 2015;94:e1939.
11.
Ismail S, Cheng L, Grigoriadou S, Laffan J, Menon M: Lesson of the month 2: the limitations of steroid therapy in bradykinin-mediated angioedema attacks. Clin Med 2015;15:101-103.
12.
Otani IM, Christiansen SC, Busse P, Camargo CA Jr, Zuraw BL, Riedl MA, Banerji A: Emergency department management of hereditary angioedema attacks: patient perspectives. J Allergy Clin Immunol Pract 2017;5:128-134.e124.
13.
Subbarayan A, Colarusso G, Hughes SM, Gennery AR, Slatter M, Cant AJ, Arkwright PD: Clinical features that identify children with primary immunodeficiency diseases. Pediatrics 2011;127:810-816.
14.
Costa-Carvalho BT, Grumach AS, Franco JL, Espinosa-Rosales FJ, Leiva LE, King A, Porras O, Bezrodnik L, Oleastro M, Sorensen RU, Condino-Neto A: Attending to warning signs of primary immunodeficiency diseases across the range of clinical practice. J Clin Immunol 2014;34:10-22.
15.
Neiberger RE: The ABC's of evaluating children with hematuria. Am Fam Physician 1994;49:623-628.
16.
Sicuro Correa L, Hökerberg YH, Oliveira RV, Barros DM, Alexandria HA, Daumas RP, Andrade CA, Passos SR, Brasil P: Use of warning signs for dengue by pediatric health care staff in Brazil. PLoS One 2016;11:e0163946.
17.
Bygum A: Hereditary angio-oedema in Denmark: a nationwide survey. Br J Dermatol 2009;161:1153-1158.
18.
Roche O, Blanch A, Caballero T, Sastre N, Callejo D, López -Trascasa M: Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol 2005;94:498-503.
19.
Zanichelli A, Arcoleo F, Barca MP, Borrelli P, Bova M, et al: A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy. Orphanet J Rare Dis 2015;10:11.
20.
Kelly M, Donnelly JP, McAnnally JR, Wang HE: National estimates of emergency department visits for angioedema and allergic reactions in the United States. Allergy Asthma Proc 2013;34:150-154.
21.
Fouche AS, Saunders EF, Craig T: Depression and anxiety in patients with hereditary angioedema. Ann Allergy Asthma Immunol 2014;112:371-375.
22.
Kim SJ, Brooks JC, Sheikh J, Kaplan MS, Goldberg BJ: Angioedema deaths in the United States, 1979-2010. Ann Allergy Asthma Immunol 2014;113:630-634.
23.
Frank MM: Hereditary angioedema: the clinical syndrome and its management in the United States. Immunol Allergy Clin North Am 2006;26:653-668.
24.
Zilberberg MD, Nathanson BH, Jacobsen T, Tillotson G: Descriptive epidemiology of hereditary angioedema emergency department visits in the United States, 2006-2007. Allergy Asthma Proc 2011;32:390-394.
25.
Jaiganesh T, Wiese M, Hollingsworth J, Hughan C, Kamara M, Wood P, Bethune C: Acute angioedema: recognition and management in the emergency department. Eur J Emerg Med 2013;20:10-17.
26.
Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE: Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension 2008;51:1624-1630.
27.
Bork K, Meng G, Staubach P, Hardt J: Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006;119:267-274.
28.
Henao MP, Kraschnewski JL, Kelbel T, Craig TJ: Diagnosis and screening of patients with hereditary angioedema in primary care. Ther Clin Risk Manag 2016;12:701-711.
29.
Bluestein HM, Hoover TA, Banerji AS, Camargo CA, Reshef A, Herscu P: Angiotensin-converting enzyme inhibitor-induced angioedema in a community hospital emergency department. Ann Allergy Asthma Immunol 2009;103:502-507.
30.
Rasmussen ER, Mey K, Bygum A: Angiotensin-converting enzyme inhibitor-induced angioedema - a dangerous new epidemic. Acta Derm Venereol 2014;94:260-264.
31.
Haymore BR, Yoon J, Mikita CP, Klote MM, DeZee KJ: Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis. Ann Allergy Asthma Immunol 2008;101:495-499.
32.
Lumry WR, Farkas H, Moldovan D, Toubi E, Baptista J, Craig T, Riedl M: Icatibant for multiple hereditary angioedema attacks across the controlled and open-label extension phases of FAST-3. Int Arch Allergy Immunol 2015;168:44-55.
33.
Petraroli A, Squeglia V, Di Paola N, Barbarino A, Bova M, Spano R, Marone G, Triggiani M: Home therapy with plasma-derived C1 inhibitor: a strategy to improve clinical outcomes and costs in hereditary angioedema. Int Arch Allergy Immunol 2015;166:259-266.
34.
Bernstein JA, Riedl M, Zacek L, Shapiro RS: Facilitating home-based treatment of hereditary angioedema. Allergy Asthma Proc 2015;36:92-99.
35.
Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H, Reshef A, Zuraw B: Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an international Working Group. Allergy 2012;67:147-157.
36.
Bernstein JA, Moellman J: Emerging concepts in the diagnosis and treatment of patients with undifferentiated angioedema. Int J Emerg Med 2012;5:39.
37.
Oswalt ML, Kemp SF: Anaphylaxis: office management and prevention. Immunol Allergy Clin North Am 2007;27:177-191.
38.
Zuraw BL, Christiansen SC: HAE pathophysiology and underlying mechanisms. Clin Rev Allergy Immunol 2016;51:216-229.
39.
Pappalardo E, Cicardi M, Duponchel C, Carugati A, Choquet S, Agostoni A, Tosi M: Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema. J Allergy Clin Immunol 2000;106:1147-1154.
40.
Rubinstein E, Stolz LE, Sheffer AL, Stevens C, Bousvaros A: Abdominal attacks and treatment in hereditary angioedema with C1-inhibitor deficiency. BMC Gastroenterol 2014;14:71.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.